COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up,Journal of the American College of Cardiology

当前位置： X-MOL 学术 › J. Am. Coll. Cardiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Journal of the American College of Cardiology ( IF 21.7 ) Pub Date : 2020-06-01 , DOI: 10.1016/j.jacc.2020.04.031
Behnood Bikdeli ₁ , Mahesh V Madhavan ₂ , David Jimenez ₃ , Taylor Chuich ₄ , Isaac Dreyfus ₄ , Elissa Driggin ₄ , Caroline Der Nigoghossian ₄ , Walter Ageno ₅ , Mohammad Madjid ₆ , Yutao Guo ₇ , Liang V Tang ₈ , Yu Hu ₈ , Jay Giri ₉ , Mary Cushman ₁₀ , Isabelle Quéré ₁₁ , Evangelos P Dimakakos ₁₂ , C Michael Gibson ₁₃ , Giuseppe Lippi ₁₄ , Emmanuel J Favaloro ₁₅ , Jawed Fareed ₁₆ , Joseph A Caprini ₁₇ , Alfonso J Tafur ₁₈ , John R Burton ₄ , Dominic P Francese ₁₉ , Elizabeth Y Wang ₄ , Anna Falanga ₂₀ , Claire McLintock ₂₁ , Beverley J Hunt ₂₂ , Alex C Spyropoulos ₂₃ , Geoffrey D Barnes ₂₄ , John W Eikelboom ₂₅ , Ido Weinberg ₂₆ , Sam Schulman ₂₇ , Marc Carrier ₂₈ , Gregory Piazza ₂₉ , Joshua A Beckman ₃₀ , P Gabriel Steg ₃₁ , Gregg W Stone ₃₂ , Stephan Rosenkranz ₃₃ , Samuel Z Goldhaber ₂₉ , Sahil A Parikh ₂ , Manuel Monreal ₃₄ , Harlan M Krumholz ₃₅ , Stavros V Konstantinides ₃₆ , Jeffrey I Weitz ₃₇ , Gregory Y H Lip ₃₈ ,

Affiliation

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.
Department of Cardiology, Chinese PLA General Hospital, Beijing, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
University of Vermont Medical Center, Burlington, Vermont.
Department of Vascular Medicine, University of Montpellier, Centre Hospitalier Universitaire Montpellier, InnoVTE F-CRIN Network, Montpellier, France.
Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece.
Harvard Medical School, Boston, Massachusetts; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.
Haematology Laboratory, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia; Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.
Loyola University Medical Center, Chicago, Illinois.
Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
Pritzker School of Medicine, University of Chicago, Chicago, Illinois; Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois.
Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.
Auckland City Hospital, Auckland, New Zealand.
St Thomas' Hospital, London, United Kingdom.
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, New York.
Center for Bioethics and Social Science in Medicine, University of Michigan, Ann Arbor, Michigan; Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan.
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Harvard Medical School, Boston, Massachusetts; Massachusetts General Hospital, Boston, Massachusetts.
Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Harvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
Vanderbilt University School of Medicine, Nashville, Tennessee.
INSERM U1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, FACT (French Alliance for Cardiovascular Trials), Paris, France; Université Paris, Paris, France; Royal Brompton Hospital, Imperial College London, London, United Kingdom.
Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Cologne Cardiovascular Research Center, Heart Center, Department of Cardiology, University of Cologne, Cologne, Germany.
Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain.
Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.
McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; Aalborg University, Aalborg, Denmark.

Abstract Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

中文翻译：

COVID-19 和血栓或血栓栓塞性疾病：对预防、抗血栓治疗和随访的影响

摘要 2019 冠状病毒病 (COVID-19) 是一种由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的病毒性呼吸道疾病，由于过度炎症，患者可能在静脉和动脉循环中容易患上血栓性疾病。、血小板活化、内皮功能障碍和停滞。此外，许多接受抗血栓治疗的血栓性疾病患者可能会患上 COVID-19，这可能会对抗血栓治疗的选择、剂量和实验室监测产生影响。此外，在高度关注 COVID-19 的时期，考虑如何优化现有技术来护理患有血栓性疾病但未患 COVID-19 的患者至关重要。在此，我们回顾了目前对发生静脉或动脉血栓形成的 COVID-19 患者、以及患有 COVID-19 的既往血栓性疾病患者或需要预防或护理的患者的发病机制、流行病学、治疗和结果的了解。他们在 COVID-19 大流行期间患有血栓性疾病。

更新日期：2020-06-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南